Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing
about
Obesity-Related Digestive Diseases and Their PathophysiologyuPA/uPAR and SERPINE1 in head and neck cancer: role in tumor resistance, metastasis, prognosis and therapy.Small Molecule Inhibitors of Plasminogen Activator Inhibitor-1 Elicit Anti-Tumorigenic and Anti-Angiogenic Activity.Intracellular Expression of PAI-1 Specific Aptamers Alters Breast Cancer Cell Migration, Invasion and Angiogenesis.Enhanced mRNA expression of plasminogen activator inhibitor-1 in livedoid vasculopathy lesions.The urokinase plasminogen activation system in gastroesophageal cancer: A systematic review and meta-analysis.Plasminogen activator inhibitor links obesity and thrombotic cerebrovascular diseases: The roles of PAI-1 and obesity on stroke.Serum Cytokines in Young Pediatric Patients with Congenital Cardiac Shunts and Altered Pulmonary Hemodynamics.Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination.5-Aminolevulinic Acid Guided Sampling of Glioblastoma Microenvironments Identifies Pro-Survival Signaling at Infiltrative Margins.Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer.A prospective study of soluble receptor for advanced glycation end products and adipokines in association with pancreatic cancer in postmenopausal women.Overexpression of Rab11-FIP2 in colorectal cancer cells promotes tumor migration and angiogenesis through increasing secretion of PAI-1.Mature and progenitor endothelial cells perform angiogenesis also under protease inhibition: the amoeboid angiogenesis.Diabetes-associated dysregulated cytokines and cancer.
P2860
Q28073381-D870CF5A-421D-4D9D-B6C8-FDD6A3794664Q30249137-3C264FB9-D2CD-475E-AB4E-2387076A29D4Q35711136-59AB29CC-2688-4319-A2D5-68C6CB5F7E40Q36166157-02B230E0-33FF-49AF-AD37-4760DA2EF0EBQ36276804-699EDED6-AD0E-460F-91C4-54BAF2001DD6Q38833520-899871BC-06AD-4866-9D34-24615DB14D84Q39220804-A28421AF-78D1-4232-B0B3-7D28D34C55A2Q41079973-A3E1C02D-5A27-42E2-942E-78EBF7E6DD35Q47126029-C5783038-BB7C-4808-8FB5-8E978BE5B700Q47134867-4D2DA562-697A-4DE2-A80E-6317D1EF78CCQ47702697-3751BC5A-4473-436E-8501-FD926259A028Q52638887-9F99FF15-3DF8-4056-AFF6-0C6DD59E1AAFQ52655258-1CA90E2F-0335-4896-A1E2-C58E35BAFC36Q54936719-4B1546A7-DD83-4DA8-9C1A-4642780C2CD9Q55331908-8E03A3A7-4BC2-427B-A712-C56F84A06B2D
P2860
Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Plasminogen Activator Inhibito ...... for Future Therapeutic Testing
@ast
Plasminogen Activator Inhibito ...... for Future Therapeutic Testing
@en
Plasminogen Activator Inhibito ...... for Future Therapeutic Testing
@nl
type
label
Plasminogen Activator Inhibito ...... for Future Therapeutic Testing
@ast
Plasminogen Activator Inhibito ...... for Future Therapeutic Testing
@en
Plasminogen Activator Inhibito ...... for Future Therapeutic Testing
@nl
prefLabel
Plasminogen Activator Inhibito ...... for Future Therapeutic Testing
@ast
Plasminogen Activator Inhibito ...... for Future Therapeutic Testing
@en
Plasminogen Activator Inhibito ...... for Future Therapeutic Testing
@nl
P2860
P3181
P1433
P1476
Plasminogen Activator Inhibito ...... for Future Therapeutic Testing
@en
P2093
Veronica R Placencio
P2860
P304
P3181
P356
10.1158/0008-5472.CAN-15-0876
P407
P50
P577
2015-07-15T00:00:00Z